Nura Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, developing neuroprotective small-molecule medicines that halt neurodegeneration before it progresses. Conceived in 2018 by The Column Group together with scientific founders Steve McKnight, PhD and Marc Freeman, PhD, the company targets SARM1 — a neuronally enriched NAD hydrolase that acts as an axon-intrinsic metabolic sensor and central driver of axonal degeneration — on the thesis that intervening early in that pathway confers durable structural and functional neuroprotection across peripheral, central and ocular nervous-system disorders. Its pipeline is led by NB-4746, a first-generation oral, brain-penetrant, reversible orthosteric SARM1 inhibitor in a global Phase 1b/2a study in ALS, and NB-9402, a mechanistically differentiated second-generation oral, covalent, irreversible, allosteric inhibitor completing a Phase 1a healthy-volunteer study in 2026. Nura Bio launched publicly in January 2020 with a $73 million Series A, extended that round with $68 million to pass $140 million raised, and closed a $73.8 million Series B in June 2026 led by The Column Group with Euclidean Capital, Samsara BioCapital and Sanofi Ventures; Shilpa Sambashivan, PhD, a co-founder and its chief scientist, serves as CEO. Its science is published in NEURON and CELL REPORTS. Nura Bio runs no developer program and publishes no product API, developer portal, API reference, SDK or pricing. The only machine-readable surfaces reachable without credentials are a published llms.txt and the WordPress REST content API behind nurabio.com, which serves the news archive, site pages, people directory and media library as JSON — both catalogued here.
Nura Bio publishes 7 APIs on the APIs.io network, including Directory API, Discovery API, Media API, and 4 more. Tagged areas include Company, Biotechnology, Pharmaceuticals, Neuroscience, and Neurodegeneration.
Nura Bio’s developer surface includes product news, authentication, and 19 more developer resources.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/nura-bio: open an issue to ask a question, or submit a pull request to add artifacts.
Submit an artifact on GitHub — free →Manage your own listing — the Influence plan, $499/mo →
The people directory — leadership, board of directors, and founders and advisors — carried on the Avada theme `portfolio` custom post type and its `portfolio_entries` taxonomy.
aid: nura-bio
name: Nura Bio
description: Nura Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California,
developing neuroprotective small-molecule medicines that halt neurodegeneration before it progresses. Conceived in 2018
by The Column Group together with scientific founders Steve McKnight, PhD and Marc Freeman, PhD, the company targets SARM1
— a neuronally enriched NAD hydrolase that acts as an axon-intrinsic metabolic sensor and central driver of axonal degeneration
— on the thesis that intervening early in that pathway confers durable structural and functional neuroprotection across
peripheral, central and ocular nervous-system disorders. Its pipeline is led by NB-4746, a first-generation oral, brain-penetrant,
reversible orthosteric SARM1 inhibitor in a global Phase 1b/2a study in ALS, and NB-9402, a mechanistically differentiated
second-generation oral, covalent, irreversible, allosteric inhibitor completing a Phase 1a healthy-volunteer study in 2026.
Nura Bio launched publicly in January 2020 with a $73 million Series A, extended that round with $68 million to pass $140
million raised, and closed a $73.8 million Series B in June 2026 led by The Column Group with Euclidean Capital, Samsara
BioCapital and Sanofi Ventures; Shilpa Sambashivan, PhD, a co-founder and its chief scientist, serves as CEO. Its science
is published in NEURON and CELL REPORTS. Nura Bio runs no developer program and publishes no product API, developer portal,
API reference, SDK or pricing. The only machine-readable surfaces reachable without credentials are a published llms.txt
and the WordPress REST content API behind nurabio.com, which serves the news archive, site pages, people directory and media
library as JSON — both catalogued here.
deliveryModel:
model: saas
open_source: false
commercial: true
callable_host: true
label: Hosted service · you call their endpoint
confidence: high
source:
- openapi
- pricing
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: self-serve
trial: false
try_now: false
public: false
label: Self-serve signup
confidence: medium
source:
- authentication
- rate-limits
- security
generated: '2026-09-02'
method: derived
image: https://nurabio.com/wp-content/uploads/2020/07/NuraBio_full_logo_grey_TM-1-1-1030x167.png
url: https://raw.githubusercontent.com/api-evangelist/nura-bio/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment-pipeline
specificationVersion: '0.20'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Neuroscience
- Neurodegeneration
- Drug Discovery
- Life Sciences
- Clinical Trials
- Rare Disease
- Small Molecule Therapeutics
- content-api
tags_raw:
- Company
- biotechnology
- pharmaceuticals
- neuroscience
- neurodegeneration
- drug-discovery
- life-sciences
- clinical-trials
- rare-disease
- small-molecule-therapeutics
- content-api
apis:
- aid: nura-bio:nura-bio-directory-api
name: Nura Bio Directory API
description: Public author projection for users who have published content.
humanURL: https://developer.wordpress.org/rest-api/
baseURL: https://nurabio.com/wp-json
tags:
- Directory
tags_raw:
- directory
properties:
- type: OpenAPI
url: openapi/nura-bio-directory-api-openapi.yml
- type: Authentication
url: authentication/nura-bio-authentication.yml
- type: Conventions
url: conventions/nura-bio-conventions.yml
- type: ErrorCatalog
url: errors/nura-bio-problem-types.yml
- type: DataModel
url: data-model/nura-bio-data-model.yml
- type: RateLimits
url: rate-limits/nura-bio-rate-limits.yml
- aid: nura-bio:nura-bio-discovery-api
name: Nura Bio Discovery API
description: Route, type, taxonomy, status and oEmbed discovery endpoints that describe the deployment itself.
humanURL: https://developer.wordpress.org/rest-api/
baseURL: https://nurabio.com/wp-json
tags:
- Discovery
tags_raw:
- discovery
properties:
- type: OpenAPI
url: openapi/nura-bio-discovery-api-openapi.yml
- type: Authentication
url: authentication/nura-bio-authentication.yml
- type: Conventions
url: conventions/nura-bio-conventions.yml
- type: ErrorCatalog
url: errors/nura-bio-problem-types.yml
- type: DataModel
url: data-model/nura-bio-data-model.yml
- type: RateLimits
url: rate-limits/nura-bio-rate-limits.yml
- aid: nura-bio:nura-bio-media-api
name: Nura Bio Media API
description: 'The media library: logo assets, team headshots, scientific figures and press-release documents.'
humanURL: https://developer.wordpress.org/rest-api/
baseURL: https://nurabio.com/wp-json
tags:
- Media
tags_raw:
- media
properties:
- type: OpenAPI
url: openapi/nura-bio-media-api-openapi.yml
- type: Authentication
url: authentication/nura-bio-authentication.yml
- type: Conventions
url: conventions/nura-bio-conventions.yml
- type: ErrorCatalog
url: errors/nura-bio-problem-types.yml
- type: DataModel
url: data-model/nura-bio-data-model.yml
- type: RateLimits
url: rate-limits/nura-bio-rate-limits.yml
- aid: nura-bio:nura-bio-pages-api
name: Nura Bio Pages API
description: 'The six evergreen site pages: Home, About Us, Our Science, News & Literature, Join Us, Contact.'
humanURL: https://developer.wordpress.org/rest-api/
baseURL: https://nurabio.com/wp-json
tags:
- Pages
tags_raw:
- pages
properties:
- type: OpenAPI
url: openapi/nura-bio-pages-api-openapi.yml
- type: Authentication
url: authentication/nura-bio-authentication.yml
- type: Conventions
url: conventions/nura-bio-conventions.yml
- type: ErrorCatalog
url: errors/nura-bio-problem-types.yml
- type: DataModel
url: data-model/nura-bio-data-model.yml
- type: RateLimits
url: rate-limits/nura-bio-rate-limits.yml
- aid: nura-bio:nura-bio-portfolio-api
name: Nura Bio Portfolio API
description: The people directory — leadership, board of directors, and founders and advisors — carried on the Avada theme
`portfolio` custom post type and its `portfolio_entries` taxonomy.
humanURL: https://developer.wordpress.org/rest-api/
baseURL: https://nurabio.com/wp-json
tags:
- Portfolio
tags_raw:
- portfolio
properties:
- type: OpenAPI
url: openapi/nura-bio-portfolio-api-openapi.yml
- type: Authentication
url: authentication/nura-bio-authentication.yml
- type: Conventions
url: conventions/nura-bio-conventions.yml
- type: ErrorCatalog
url: errors/nura-bio-problem-types.yml
- type: DataModel
url: data-model/nura-bio-data-model.yml
- type: RateLimits
url: rate-limits/nura-bio-rate-limits.yml
- aid: nura-bio:nura-bio-posts-api
name: Nura Bio Posts API
description: The company news archive — press releases and financing, clinical and publication announcements.
humanURL: https://developer.wordpress.org/rest-api/
baseURL: https://nurabio.com/wp-json
tags:
- Posts
tags_raw:
- posts
properties:
- type: OpenAPI
url: openapi/nura-bio-posts-api-openapi.yml
- type: Authentication
url: authentication/nura-bio-authentication.yml
- type: Conventions
url: conventions/nura-bio-conventions.yml
- type: ErrorCatalog
url: errors/nura-bio-problem-types.yml
- type: DataModel
url: data-model/nura-bio-data-model.yml
- type: RateLimits
url: rate-limits/nura-bio-rate-limits.yml
- aid: nura-bio:nura-bio-taxonomy-api
name: Nura Bio Taxonomy API
description: Category and tag terms applied to the news archive.
humanURL: https://developer.wordpress.org/rest-api/
baseURL: https://nurabio.com/wp-json
tags:
- Taxonomy
tags_raw:
- taxonomy
properties:
- type: OpenAPI
url: openapi/nura-bio-taxonomy-api-openapi.yml
- type: Authentication
url: authentication/nura-bio-authentication.yml
- type: Conventions
url: conventions/nura-bio-conventions.yml
- type: ErrorCatalog
url: errors/nura-bio-problem-types.yml
- type: DataModel
url: data-model/nura-bio-data-model.yml
- type: RateLimits
url: rate-limits/nura-bio-rate-limits.yml
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: Website
url: https://nurabio.com/
- type: About
url: https://nurabio.com/about-us/
- type: Science
url: https://nurabio.com/our-science/
- type: News
url: https://nurabio.com/news-and-literature/
- type: BlogRSS
url: https://nurabio.com/feed/
- type: Careers
url: https://nurabio.com/join-us/
- type: ContactForm
url: https://nurabio.com/contact/
- type: LinkedIn
url: https://www.linkedin.com/company/nurabio
- type: LLMsTxt
url: llms/nura-bio-llms.txt
- type: Authentication
url: authentication/nura-bio-authentication.yml
- type: Conventions
url: conventions/nura-bio-conventions.yml
- type: Conformance
url: conformance/nura-bio-conformance.yml
- type: ErrorCatalog
url: errors/nura-bio-problem-types.yml
- type: Lifecycle
url: lifecycle/nura-bio-lifecycle.yml
- type: DataModel
url: data-model/nura-bio-data-model.yml
- type: RateLimits
url: rate-limits/nura-bio-rate-limits.yml
- type: Plans
url: plans/nura-bio-plans-pricing.yml
- type: Packages
url: packages/nura-bio-packages.yml
- type: DomainSecurity
url: security/nura-bio-domain-security.yml
- type: AgentSkill
url: skills/_index.yml
- type: Overlay
url: overlays/nura-bio-content-api-overlay.yaml
x-enrichment:
date: '2026-08-26'
status: enriched
artifacts_added: 20
pass: local-v1
x-coverage:
state: covered
reason: no-machine-readable-spec
detail: 'Nura Bio is a clinical-stage biopharmaceutical company with no developer program, no product API and no published
OpenAPI, but STEP 0b contract discovery did not come back empty: nurabio.com serves a 200 llms.txt and a 269-route WordPress
REST index at /wp-json/, from which a 24-operation read-only content API was derived and verified live.'
evidence:
- url: https://nurabio.com/wp-json/
status: 200
- url: https://nurabio.com/llms.txt
status: 200
- url: https://nurabio.com/openapi.json
status: 404
- url: https://nurabio.com/.well-known/agent-card.json
status: 404
- url: https://nurabio.com/wp-json/mcp/mcp-adapter-default-server
status: 404
checked: '2026-08-26'
Kin Score
How this is scored →